Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Irritable Bowel Syndrome

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 118 articles:
HTML format



Single Articles


    December 2020
  1. PERTTU L, Jonna J, Anna H, Eero M, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-which improvements are required? Authors' reply.
    Aliment Pharmacol Ther. 2020;52.
    PubMed    


  2. EL-SALHY M, Hausken T, Gunnar Hatlebakk J
    Letter: faecal microbiota transplantation for irritable bowel syndrome-which improvements are required?
    Aliment Pharmacol Ther. 2020;52.
    PubMed    


    October 2020
  3. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Letter: placebo run-in for IBS clinical trials - is it useful? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1239-1240.
    PubMed    


  4. BOSMAN MHMA, Keszthelyi D
    Letter: placebo run-in for IBS clinical trials-is it useful?
    Aliment Pharmacol Ther. 2020;52:1237-1238.
    PubMed    


    September 2020
  5. IANIRO G, Porcari S, Ford AC, Gasbarrini A, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement.
    Aliment Pharmacol Ther. 2020;52:923-924.
    PubMed    


  6. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:925-926.
    PubMed    


    August 2020
  7. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Letter: faecal microbiota transplantation for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:557-558.
    PubMed    


  8. XU E, Vilella RC, Segal JP, Mullish BH, et al
    Letter: faecal microbiota transplantation for IBS.
    Aliment Pharmacol Ther. 2020;52:556-557.
    PubMed     Abstract available


  9. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Editorial: minesapride for irritable bowel syndrome with constipation-authors' reply.
    Aliment Pharmacol Ther. 2020;52:715-716.
    PubMed    


  10. BLACK CJ, Barberio B, Ford AC
    Editorial: minesapride for irritable bowel syndrome with constipation.
    Aliment Pharmacol Ther. 2020;52:713-714.
    PubMed    


    June 2020
  11. HAMATANI T, Fukudo S, Nakada Y, Inada H, et al
    Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
    Aliment Pharmacol Ther. 2020 Jun 25. doi: 10.1111/apt.15907.
    PubMed     Abstract available


  12. GIBSON PR, Halmos EP, Muir JG
    Review article: FODMAPS, prebiotics and gut health. The FODMAP hypothesis revisited.
    Aliment Pharmacol Ther. 2020 Jun 20. doi: 10.1111/apt.15818.
    PubMed     Abstract available


  13. OSTOJIC SM
    Letter: balancing gut hydrogen as a proxy for bacteriotherapy benefits in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020;51:1451-1452.
    PubMed    


    May 2020
  14. RAO SSC, Xiang X, Yan Y, Rattanakovit K, et al
    Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
    Aliment Pharmacol Ther. 2020 May 13. doi: 10.1111/apt.15772.
    PubMed     Abstract available


  15. BASILISCO G, Barbara G, Bellini M, Cataudella G, et al
    Editorial: symptom improvement does not equal satisfaction with treatment for constipation-authors' reply.
    Aliment Pharmacol Ther. 2020;51:910-911.
    PubMed    


  16. BALLOU S, Lembo A
    Editorial: symptom improvement does not equal satisfaction with treatment for constipation.
    Aliment Pharmacol Ther. 2020;51:909-910.
    PubMed    


    April 2020
  17. LAHTINEN P, Jalanka J, Hartikainen A, Mattila E, et al
    Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15740.
    PubMed     Abstract available


    February 2020
  18. BASILISCO G
    Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients.
    Aliment Pharmacol Ther. 2020 Feb 12. doi: 10.1111/apt.15657.
    PubMed     Abstract available


    January 2020
  19. REJ A, Buckle RL, Shaw CC, Trott N, et al
    Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2020;51:184-185.
    PubMed    


  20. TUCK C, Vanner S, Camilleri M, Jing Wang X, et al
    Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:185-186.
    PubMed    


  21. FORD AC
    Commentary: estimating the prevalence of IBS globally-past, present and future.
    Aliment Pharmacol Ther. 2020;51:198-199.
    PubMed    


  22. VAKIL N
    Commentary: tegaserod and IBS, two decades on.
    Aliment Pharmacol Ther. 2020;51:200-201.
    PubMed    


    October 2019
  23. GUNN D, Garsed K, Lam C, Singh G, et al
    Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:826-827.
    PubMed    


  24. BLACK CJ, Ford AC, Houghton LA
    Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer?
    Aliment Pharmacol Ther. 2019;50:825-826.
    PubMed    


    July 2019
  25. GUNN D, Garsed K, Lam C, Singh G, et al
    Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron.
    Aliment Pharmacol Ther. 2019 Jul 24. doi: 10.1111/apt.15420.
    PubMed     Abstract available


  26. CREED F
    Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies.
    Aliment Pharmacol Ther. 2019 Jul 17. doi: 10.1111/apt.15396.
    PubMed     Abstract available


  27. WANG XJ, Camilleri M, Vanner S, Tuck C, et al
    Review article: biological mechanisms for symptom causation by individual FODMAP subgroups - the case for a more personalised approach to dietary restriction.
    Aliment Pharmacol Ther. 2019 Jul 15. doi: 10.1111/apt.15419.
    PubMed     Abstract available


    June 2019
  28. ZAMANI M, Alizadeh-Tabari S, Zamani V
    Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2019 Jun 3. doi: 10.1111/apt.15325.
    PubMed     Abstract available


    May 2019
  29. IANIRO G, Eusebi LH, Black CJ, Gasbarrini A, et al
    Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2019 May 28. doi: 10.1111/apt.15330.
    PubMed     Abstract available


  30. FORD AC, Harris LA, Lacy BE, Quigley EMM, et al
    Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1254-1255.
    PubMed    


  31. SUN P, Zhang W, Miao Y, Chen Z, et al
    Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS.
    Aliment Pharmacol Ther. 2019;49:1253-1254.
    PubMed    


    April 2019
  32. BOND A, Probert C
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1087-1088.
    PubMed    


  33. KESHTELI AH, Madsen KL, Mandal R, Boeckxstaens GE, et al
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1088-1089.
    PubMed    


  34. LEONG RWL, Kaakoush NO, Yau YY, Wasinger VC, et al
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome?
    Aliment Pharmacol Ther. 2019;49:1086-1087.
    PubMed    


  35. MITCHELL H, Porter J, Gibson PR, Barrett J, et al
    Letters: low FODMAP diet-directions for future research and the low FODMAP diet is not the only diet for IBS-authors' reply.
    Aliment Pharmacol Ther. 2019;49:1109-1110.
    PubMed    


  36. O'BRIEN L, Brown S, Gearry RB, Day AS, et al
    Letter: low FODMAP diet-directions for future research.
    Aliment Pharmacol Ther. 2019;49:1107-1108.
    PubMed    


  37. REJ A, Trott N, Sanders DS, Aziz I, et al
    Letter: the low FODMAP diet is not the only diet for IBS.
    Aliment Pharmacol Ther. 2019;49:1108-1109.
    PubMed    


    February 2019
  38. VIJAYVARGIYA P, Camilleri M, Burton D, Busciglio I, et al
    Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2019 Feb 10. doi: 10.1111/apt.15106.
    PubMed     Abstract available


    January 2019
  39. KESHTELI AH, Madsen KL, Mandal R, Boeckxstaens GE, et al
    Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.
    Aliment Pharmacol Ther. 2019 Jan 31. doi: 10.1111/apt.15141.
    PubMed     Abstract available


  40. KOLOSKI N, Jones M, Walker MM, Veysey M, et al
    Population based study: atopy and autoimmune diseases are associated with functional dyspepsia and irritable bowel syndrome, independent of psychological distress.
    Aliment Pharmacol Ther. 2019 Jan 27. doi: 10.1111/apt.15120.
    PubMed     Abstract available


  41. SAITO YA, Almazar AE, Tilkes KE, Choung RS, et al
    Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2019 Jan 20. doi: 10.1111/apt.15077.
    PubMed     Abstract available


  42. MITCHELL H, Porter J, Gibson PR, Barrett J, et al
    Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome-directions for future research.
    Aliment Pharmacol Ther. 2019;49:124-139.
    PubMed     Abstract available


    October 2018
  43. FORD AC, Harris LA, Lacy BE, Quigley EMM, et al
    Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2018 Oct 8. doi: 10.1111/apt.15001.
    PubMed     Abstract available


  44. RIBOLSI M, Cicala M, Zentilin P, Neri M, et al
    Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Aliment Pharmacol Ther. 2018 Oct 7. doi: 10.1111/apt.14986.
    PubMed     Abstract available


    September 2018
  45. ALBUSODA A, Ruffle JK, Friis KA, Gysan MR, et al
    Systematic review and meta-analysis: conditioned pain modulation in patients with the irritable bowel syndrome.
    Aliment Pharmacol Ther. 2018 Sep 11. doi: 10.1111/apt.14965.
    PubMed     Abstract available


  46. LACY BE
    Review article: an analysis of safety profiles of the treatments for diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2018 Sep 7. doi: 10.1111/apt.14948.
    PubMed     Abstract available


    August 2018
  47. CHEN M, Zheng H, Huang DQ
    Editorial: Tong-Xie-Yao-Fang (TXYF) for irritable bowel syndrome with diarrhoea (IBS-D)-ancient medicine meets modern study. Authors' reply.
    Aliment Pharmacol Ther. 2018;48:486-487.
    PubMed    


  48. VITTA S, Sayuk GS
    Editorial: Tong-Xie-Yao-Fang (TXYF) for irritable bowel syndrome with diarrhoea (IBS-D)-ancient medicine meets modern study.
    Aliment Pharmacol Ther. 2018;48:485-486.
    PubMed    


    June 2018
  49. HANLON I, Hewitt C, Bell K, Phillips A, et al
    Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 14. doi: 10.1111/apt.14840.
    PubMed     Abstract available


  50. CHEN M, Tang TC, Wang Y, Shui J, et al
    Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2018 Jun 1. doi: 10.1111/apt.14817.
    PubMed     Abstract available


  51. WHORWELL PJ
    Editorial: preventing unnecessary investigation and surgery in the irritable bowel syndrome-the critical role of the general practitioner.
    Aliment Pharmacol Ther. 2018;47:1558-1559.
    PubMed    


    March 2018
  52. CLEVERS E, Vaes B, Henrard S, Goderis G, et al
    Health problems associated with irritable bowel syndrome: analysis of a primary care registry.
    Aliment Pharmacol Ther. 2018 Mar 24. doi: 10.1111/apt.14612.
    PubMed     Abstract available


    February 2018
  53. HUNGIN APS, Mitchell CR, Whorwell P, Mulligan C, et al
    Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus.
    Aliment Pharmacol Ther. 2018 Feb 20. doi: 10.1111/apt.14539.
    PubMed     Abstract available


  54. MUIR JG, Iacovou M
    Editorial: irritable bowel syndrome-in addition to having properly-trained dietitians, is it time to add a yoga teacher to our multidisciplinary team?
    Aliment Pharmacol Ther. 2018;47:432-433.
    PubMed    


  55. UNO Y
    Letter: irritable bowel syndrome-how a low-FODMAP diet or yoga might help.
    Aliment Pharmacol Ther. 2018;47:444-445.
    PubMed    


  56. SCHUMANN D, Cramer H
    Editorial: irritable bowel syndrome-in addition to having properly-trained dietitians, is it time to add a yoga teacher to our multidisciplinary team? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:433-434.
    PubMed    


  57. SCHUMANN D, Cramer H
    Letter: irritable bowel syndrome-how a low-FODMAP diet or yoga might help. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:445-446.
    PubMed    


    January 2018
  58. CHUMPITAZI BP, Kearns GL, Shulman RJ
    Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders.
    Aliment Pharmacol Ther. 2018 Jan 26. doi: 10.1111/apt.14519.
    PubMed     Abstract available


  59. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Meade L, et al
    Systematic review: psychosocial factors associated with pain in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14493.
    PubMed     Abstract available


  60. SAYUK GS, Kanuri N, Gyawali CP, Gott BM, et al
    Opioid medication use in patients with gastrointestinal diagnoses vs unexplained gastrointestinal symptoms in the US Veterans Health Administration.
    Aliment Pharmacol Ther. 2018 Jan 12. doi: 10.1111/apt.14503.
    PubMed     Abstract available


  61. BORTOLOTTI M
    Letter: the neglected analgesic properties of red pepper in the clinical management of the irritable bowel syndrome pain.
    Aliment Pharmacol Ther. 2018;47:153-154.
    PubMed    


  62. BECKERS AB, Weerts ZZRM, Masclee AAM, Keszthelyi D, et al
    Letter: the neglected analgesic properties of red pepper in the clinical management of the irritable bowel syndrome pain-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:154-155.
    PubMed    


    November 2017
  63. UNO Y
    Letter: low-FODMAP diet for exercise-induced gastrointestinal syndrome.
    Aliment Pharmacol Ther. 2017;46:1021-1022.
    PubMed    


  64. COSTA RJS, Snipe RMJ, Kitic CM, Gibson PR, et al
    Letter: low-FODMAP diet for exercise-induced gastrointestinal syndrome-Authors' reply.
    Aliment Pharmacol Ther. 2017;46:1023-1024.
    PubMed    


    October 2017
  65. SCHUMANN D, Langhorst J, Dobos G, Cramer H, et al
    Randomised clinical trial: yoga vs a low-FODMAP diet in patients with irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017 Oct 27. doi: 10.1111/apt.14400.
    PubMed     Abstract available


  66. BLACK CJ, Ford AC
    Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation?
    Aliment Pharmacol Ther. 2017;46:697.
    PubMed    


  67. POLSTER A, Van Oudenhove L, Jones M, Ohman L, et al
    Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:698-699.
    PubMed    


    September 2017
  68. BECKERS AB, Weerts ZZRM, Helyes Z, Masclee AAM, et al
    Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017 Sep 8. doi: 10.1111/apt.14294.
    PubMed     Abstract available


  69. ALEXAKIS C, Kumar S, Saxena S, Hotopf M, et al
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care-authors' reply.
    Aliment Pharmacol Ther. 2017;46:554-555.
    PubMed    


    August 2017
  70. KROGSGAARD LR, Lyngesen M, Bytzer P
    Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome-getting the facts right. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:386-387.
    PubMed    


  71. GIBSON PR, Halmos EP, Muir JG
    Letter: bias in clinical trials of the symptomatic effects of the low FODMAP diet for irritable bowel syndrome-getting the facts right.
    Aliment Pharmacol Ther. 2017;46:385-386.
    PubMed    


  72. DAMAS OM, Schwartz SJ, Abreu MT
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2017;46:467.
    PubMed    


    July 2017
  73. VIJAYVARGIYA P, Camilleri M, Carlson P, Lueke A, et al
    Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea.
    Aliment Pharmacol Ther. 2017 Jul 10. doi: 10.1111/apt.14214.
    PubMed     Abstract available


  74. POLSTER A, Van Oudenhove L, Jones M, Ohman L, et al
    Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms.
    Aliment Pharmacol Ther. 2017 Jul 3. doi: 10.1111/apt.14207.
    PubMed     Abstract available


  75. QUIGLEY EMM
    Editorial: food for thought-the low-FODMAP diet and IBS in perspective.
    Aliment Pharmacol Ther. 2017;46:206-207.
    PubMed    


    May 2017
  76. QUIGLEY EM
    Editorial: diet, inflammation and irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017;45:1278-1279.
    PubMed    


  77. SOOD R, Gracie DJ, Gold MJ, To N, et al
    Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1268-1269.
    PubMed    


  78. BALLOU S, Lembo A
    Editorial: latent class analysis to improve confidence in the diagnosis of IBS.
    Aliment Pharmacol Ther. 2017;45:1267-1268.
    PubMed    


    April 2017
  79. KROGSGAARD LR, Lyngesen M, Bytzer P
    Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017 Apr 25. doi: 10.1111/apt.14065.
    PubMed     Abstract available


  80. WHITEHEAD WE, Duffy K, Sharpe J, Nabata T, et al
    Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1005.
    PubMed    


  81. NEE J, Lembo A
    Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2017;45:1004-1005.
    PubMed    


  82. STAUDACHER HM, Cox SR
    Editorial: metabolic adaptation of colonic microbiota to galactooligosaccharides - good news for prebiotics in irritable bowel syndrome?
    Aliment Pharmacol Ther. 2017;45:1005-1006.
    PubMed    


    March 2017
  83. CHEY WD, Dove LS, Andrae DA, Covington PS, et al
    Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14031.
    PubMed     Abstract available


    February 2017
  84. PORTER CK, Welsh M, Riddle MS, Nieh C, et al
    Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13991.
    PubMed     Abstract available


  85. CREMON C, Stanghellini V, Barbaro MR, Cogliandro RF, et al
    Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017 Feb 6. doi: 10.1111/apt.13958.
    PubMed     Abstract available


  86. XU XJ, Yao SK
    Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:568-569.
    PubMed    


  87. BENNET SM, Tornblom H
    Editorial: increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017;45:567-568.
    PubMed    


  88. SOOD R, Ford AC
    Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test?
    Aliment Pharmacol Ther. 2017;45:563-564.
    PubMed    


    January 2017
  89. SOOD R, Gracie DJ, Gold MJ, To N, et al
    Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis.
    Aliment Pharmacol Ther. 2017 Jan 20. doi: 10.1111/apt.13949.
    PubMed     Abstract available


  90. WHITEHEAD WE, Duffy K, Sharpe J, Nabata T, et al
    Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2017;45:14-26.
    PubMed     Abstract available


    November 2016
  91. KONIG J, Siebenhaar A, Hogenauer C, Arkkila P, et al
    Consensus report: faecal microbiota transfer - clinical applications and procedures.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13868.
    PubMed     Abstract available


  92. AGGIO RB, White P, Jayasena H, de Lacy Costello B, et al
    Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13822.
    PubMed     Abstract available


  93. XU XJ, Zhang YL, Liu L, Pan L, et al
    Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study.
    Aliment Pharmacol Ther. 2016 Nov 9. doi: 10.1111/apt.13848.
    PubMed     Abstract available


    October 2016
  94. PETERS SL, Yao CK, Philpott H, Yelland GW, et al
    Editorial: gut-directed hypnotherapy or low FODMAP diet for the treatment of irritable bowel syndrome? Authors' reply.
    Aliment Pharmacol Ther. 2016;44:902-3.
    PubMed    


  95. LOVDAHL J, Storsrud S, Tornblom H
    Editorial: gut-directed hypnotherapy or low FODMAP diet for the treatment of irritable bowel syndrome?
    Aliment Pharmacol Ther. 2016;44:901-2.
    PubMed    


    September 2016
  96. CHANG L, Chey WD, Drossman D, Losch-Beridon T, et al
    Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.
    Aliment Pharmacol Ther. 2016 Sep 27. doi: 10.1111/apt.13807.
    PubMed     Abstract available


    August 2016
  97. BLAKE MR, Raker JM, Whelan K
    Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2016 Aug 5. doi: 10.1111/apt.13746.
    PubMed     Abstract available


  98. DIEDEREN K, Hoekman DR, Benninga MA
    Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:309-10.
    PubMed    


  99. DAI C, Jiang M, Sun MJ
    Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;44:308-9.
    PubMed    


    July 2016
  100. KOLOSKI NA, Jones M, Talley NJ
    Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study.
    Aliment Pharmacol Ther. 2016 Jul 22. doi: 10.1111/apt.13738.
    PubMed     Abstract available


  101. WADHWA A, Al Nahhas MF, Dierkhising RA, Patel R, et al
    High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.
    Aliment Pharmacol Ther. 2016 Jul 22. doi: 10.1111/apt.13737.
    PubMed     Abstract available


  102. LAATIKAINEN R, Koskenpato J, Hongisto SM, Loponen J, et al
    Randomised clinical trial: low-FODMAP rye bread vs. regular rye bread to relieve the symptoms of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2016 Jul 15. doi: 10.1111/apt.13726.
    PubMed     Abstract available


  103. PETERS SL, Yao CK, Philpott H, Yelland GW, et al
    Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2016 Jul 11. doi: 10.1111/apt.13706.
    PubMed     Abstract available


    May 2016
  104. PATEL A, Hasak S, Cassell B, Ciorba MA, et al
    Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome.
    Aliment Pharmacol Ther. 2016 May 30. doi: 10.1111/apt.13677.
    PubMed     Abstract available


  105. BARANSKA A, Mujagic Z, Smolinska A, Dallinga JW, et al
    Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach.
    Aliment Pharmacol Ther. 2016 May 2. doi: 10.1111/apt.13654.
    PubMed     Abstract available


    April 2016
  106. DIEDEREN K, Hoekman DR, Hummel TZ, de Meij TG, et al
    The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Aliment Pharmacol Ther. 2016 Apr 25. doi: 10.1111/apt.13636.
    PubMed     Abstract available


    March 2016
  107. MUJAGIC Z, Keszthelyi D, Thijssen AY, Jonkers DM, et al
    Editorial: serotonin and irritable bowel syndrome - reconciling pharmacological effects with basic biology; authors' reply.
    Aliment Pharmacol Ther. 2016;43:646-7.
    PubMed    


  108. QUIGLEY EM
    Editorial: serotonin and irritable bowel syndrome - reconciling pharmacological effects with basic biology.
    Aliment Pharmacol Ther. 2016;43:644-6.
    PubMed    


    February 2016
  109. GUAGNOZZI D, Arias A, Lucendo AJ
    Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders.
    Aliment Pharmacol Ther. 2016 Feb 24. doi: 10.1111/apt.13573.
    PubMed     Abstract available


    January 2016
  110. HUNGIN AP, Paxman L, Koenig K, Dalrymple J, et al
    Prevalence, symptom patterns and management of episodic diarrhoea in the community: a population-based survey in 11 countries.
    Aliment Pharmacol Ther. 2016 Jan 8. doi: 10.1111/apt.13513.
    PubMed     Abstract available


  111. PIMENTEL M
    Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2016;43 Suppl 1:37-49.
    PubMed     Abstract available


  112. DUPONT HL
    Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    Aliment Pharmacol Ther. 2016;43 Suppl 1:1-2.
    PubMed     Abstract available


    December 2015
  113. CHUMPITAZI BP, Shulman RJ
    Letter: avoid FODMAPs or follow simple tips--authors' reply.
    Aliment Pharmacol Ther. 2015;42.
    PubMed    


  114. MENNINI M, Ferrari F
    Letter: avoid FODMAPs or follow simple tips?
    Aliment Pharmacol Ther. 2015;42.
    PubMed    


    November 2015
  115. GOTTLIEB K, Wacher V, Sliman J, Pimentel M, et al
    Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.
    Aliment Pharmacol Ther. 2015 Nov 11. doi: 10.1111/apt.13469.
    PubMed     Abstract available


  116. THIJSSEN AY, Mujagic Z, Jonkers DM, Ludidi S, et al
    Alterations in serotonin metabolism in the irritable bowel syndrome.
    Aliment Pharmacol Ther. 2015 Nov 5. doi: 10.1111/apt.13459.
    PubMed     Abstract available


  117. YAO CK, Muir JG, Gibson PR
    Review article: insights into colonic protein fermentation, its modulation and potential health implications.
    Aliment Pharmacol Ther. 2015 Nov 2. doi: 10.1111/apt.13456.
    PubMed     Abstract available


    September 2015
  118. RANGEL I, Sundin J, Fuentes S, Repsilber D, et al
    The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects.
    Aliment Pharmacol Ther. 2015 Sep 17. doi: 10.1111/apt.13399.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Irritable Bowel Syndrome is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: